<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-02-26</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-02-26</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>53</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
FGFRæŠ‘åˆ¶å‰‚åœ¨PIK3CAé©±åŠ¨çš„å­å®«å†…è†œç™Œä¸­å…‹æœæ²»ç–—è€è¯æ€§å’Œå…ç–«é€ƒé€¸ï¼Œä»¥åŠç”Ÿé…®é¥®é£Ÿè”åˆç–—æ³•å¢å¼ºFLT3-ITDæ€¥æ€§é«“ç³»ç™½è¡€ç—…æ²»ç–—æ•ˆæœã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤ä»£è°¢è°ƒæ§ä¸ç™Œç—‡æ²»ç–—ï¼šç ”ç©¶ç”Ÿé…®é¥®é£Ÿå¯¹æ€¥æ€§é«“ç³»ç™½è¡€ç—…çš„ä½œç”¨ï¼Œä»¥åŠæ°®ä»£è°¢é€šè·¯åœ¨ç»†èƒçŠ¶æ€ä¸­çš„ä½œç”¨ã€‚<br />
- ä¿¡å·é€šè·¯ä¸ç™Œç—‡è¿›å±•ï¼šæ¢ç´¢FGFRæŠ‘åˆ¶å‰‚åœ¨å­å®«å†…è†œç™Œä¸­çš„ç–—æ•ˆï¼Œä»¥åŠåŸºå› ç»„é‡æ’å¯¹ä¹³è…ºç™Œè¿›å±•çš„å½±å“ã€‚<br />
- å…ç–«ç»†èƒåŠŸèƒ½ä¸è°ƒæ§ï¼šç ”ç©¶DOT1Lå¯¹æ ‘çªçŠ¶ç»†èƒäºšç¾¤å‘è‚²çš„å½±å“ï¼Œä»¥åŠciliatedç»†èƒé€šè¿‡STINGä»‹å¯¼çš„å…ç–«ç‹¬ç«‹æœºåˆ¶æŠ‘åˆ¶è‚¿ç˜¤å‘ç”Ÿã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- ç»“åˆé«˜é€šé‡æµ‹åºï¼ˆRNA-Seq, ChIP-Seq, ATAC-Seq, scRNA-Seqï¼‰ä¸ç”Ÿç‰©ä¿¡æ¯å­¦åˆ†æï¼Œæ·±å…¥è§£æåŸºå› ç»„ã€è½¬å½•ç»„åŠè¡¨è§‚é—ä¼ å­¦å˜åŒ–ã€‚<br />
- æ„å»ºäº†é¦–ä¸ªä¸´åºŠç›¸å…³çš„ã€å…ç–«æ´»æ€§çš„PIK3CAé©±åŠ¨çš„å­å®«å†…è†œç™Œå°é¼ æ¨¡å‹ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ç ”ç©¶å‘ç°ï¼Œé˜¿å°”èŒ¨æµ·é»˜ç—…å¯èƒ½å§‹äºå¤§è„‘è¡€æµçš„æ—©æœŸã€æ— å£°ä¸‹é™ï¼Œè¿™ä¸€å˜åŒ–ä¸æ·€ç²‰æ ·è›‹ç™½æ–‘å—å’Œæµ·é©¬ä½“èç¼©ç­‰ç–¾ç—…æ ‡å¿—ç‰©å¯†åˆ‡ç›¸å…³ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- æ¢ç´¢å¤§è„‘è¡€æµå’Œæ°§æ°”æ¶ˆè€—çš„æ—©æœŸæ”¹å˜ä½œä¸ºé˜¿å°”èŒ¨æµ·é»˜ç—…è¯Šæ–­çš„æ½œåœ¨æŒ‡æ ‡ã€‚<br />
- å…³è”å¤§è„‘è¡€æµå˜åŒ–ä¸æ·€ç²‰æ ·è›‹ç™½æ²‰ç§¯åŠè®°å¿†åŠŸèƒ½å—æŸä¹‹é—´çš„æœºåˆ¶ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- æå‡ºåˆ©ç”¨ç®€å•ã€æ— åˆ›æ€§æ‰«ææŠ€æœ¯è¿›è¡Œæ—©æœŸæ£€æµ‹çš„å¯èƒ½æ€§ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (52æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE319824 ç”Ÿé…®é¥®é£Ÿé¶å‘è°ƒèŠ‚å…¨èº«å’Œè‚¿ç˜¤ä»£è°¢å¹³è¡¡å¯å¢å¼ºFLT3-ITDæ€¥æ€§é«“ç³»ç™½è¡€ç—…çš„æ²»ç–—æ•ˆæœ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€leukemiaã€metabolic<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jean-Emmanuel Sarry ; Fanny Granat ; LÃ©a Goupille ; Ambrine Sahal ; Tony KaomaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensFMS-like tyrosine kinase 3 (FLT3) mutations in acute myeloid leukemia (AML) are associated with adverse prognosis. FLT3 inhibitors (FLT3i) improve therapeutic response, however diverse resistance mechanisms such as adaptations in lipid metabolism have been identified. We hypothesized that a lipid-rich ketogenic diet (KD) might alter both host and tumoral lipid metabolism, enhancing responses to FLT3i. In FLT3-mutated AML mouse models, three weeks of lard- or plant-based KD improved efficacy of FLT3i by two-fold reduction of engraftment and tumor burden. KD increased ketone bodies and lipid accumulation in plasma, liver and AML cells, and also induced a PUFA:MUFA imbalance. KD impacted pentoses, hexoses and amino acid metabolism, enhancing sugar phosphates and vitamins in host. Mechanistically, KD rewired anabolism towards fatty acid oxidation and glycine-utilizing pathways, modulated the expression of FLT3 signaling pathways and lipid biosynthesis, and promoted tumor cell differentiation. In conclusion, this study shows that KD reduces FLT3i-resistance, offering a promising therapeutic solution.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319824" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE311373 FGFRæŠ‘åˆ¶å‰‚å…‹æœè‡´ç™Œæ€§PIK3CAé©±åŠ¨çš„æµ†æ¶²æ€§å­å®«å†…è†œç™Œçš„æ²»ç–—è€è¯æ€§å’Œå…ç–«é€ƒé€¸</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€regex:onco(logy|logist|gene|genic)ã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Xin ChengSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Mus musculusWe developed the first clinically relevant, immunocompetent SEC mouse model incorporating PIK3CA mutation, TP53 loss, and MYC overexpression. Through comprehensive analysis integrating mouse models, human cell lines, xenografts, and clinical samples, we investigated mechanisms of PIK3CA-targeted therapy resistance. Single-cell transcriptional profiling identified FGFR1/2 association with intrinsic resistance and FGFR3 with acquired resistance. Dual inhibition of FGFR and PI3Ka achieved enhanced tumor suppression. Additionally, we discovered that FGFR signaling promotes immune evasion by downregulating MHC-I/HLA-mediated antigen processing and presentation. Importantly, FGFR inhibition not only reversed immune suppression by restoring antigen presentation but also demonstrated a synergistic effect with anti-PD-1 therapy, enhancing immunotherapy response and anti-tumor immune memory. Our findings reveal FGFR's dual role in therapy resistance and immune evasion, supporting FGFR inhibition as a promising strategy to enhance treatment outcome in SEC patients.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311373" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE301939 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ DOT1L å½±å“æ ‘çªçŠ¶ç»†èƒäºšç¾¤çš„å‘è‚² [ChIP-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šdendritic cellã€ChIP-seqã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Willem-Jan de Leeuw ; Anne Mensink ; Rianne G Bouma ; Fred van Leeuwen ; Joke M den HaanSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusDendritic cells (DCs) are important orchestrators of immune responses and can be divided into two conventional DC subsets, cDC1s and cDC2s, and a plasmacytoid DC (pDC) subset, which are involved in the activation of T cells and production of type I interferons (IFNs), respectively. The development of the DC subsets occurs in the bone marrow (BM) under control of different transcription factors and epigenetic modifiers. The histone methyltransferase DOT1L, known as a druggable target in cancer, is emerging as a key epigenetic regulator of differentiation in lymphocytes. DOT1L writes methylation of lysine 79 of histone H3 in gene bodies of actively transcribed genes. Deletion or inhibition of DOT1L affects the differentiation trajectory of innate and adaptive immune cells, leading to altered cell states. Recent studies suggest that DOT1L also plays a role in DC function. Here, we investigated the role of DOT1L in the development of DCs in in vitro BM cultures and in vivo using a tamoxifen-inducible mouse model. H3K79me2 ChIPseq data of sorted DC subsets from the BM revealed distinct H3K79me2 peaks for all three subsets, which suggested differential regulation of the subsets by DOT1L. A comparison of the H3K79me2 ChIPseq data to bulk RNAseq of sorted DC subsets from the BM revealed a stronger correlation between H3K79me2 and global transcription in pDCs and cDC2s compared to cDC1s. In line with this, we observed that Dot1l deletion led to a decrease in pDCs and CpG A-stimulated IFNÎ± production and an increase in cDC2s in in vitro BM cultures, while cDC1s were unchanged. In vivo deletion of Dot1l led to a decrease in common myeloid progenitors (CMPs), monocyte DC progenitors (MDPs), and common DC progenitors (CDPs) in the BM, while common lymphoid progenitor (CLP) and cDC2 numbers were increased. Inhibition of DOT1L resulted in a similar phenotype, which linked the observed effects to the methyltransferase activity of DOT1L. Interestingly, all Dot1l-KO DC subsets exhibited an enrichment of pathways related to antigen presentation and the immune response and MHCII expression was upregulated in Dot1l-KO pDCs and cDC2s in vivo. To conclude, our data indicate that DOT1L function differentially affects the development of DCs with predominant effects in pDCs and cDC...<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301939" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE301937 ç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶ DOT1L å½±å“æ ‘çªçŠ¶ç»†èƒäºšç¾¤çš„å‘è‚² [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šdendritic cellã€RNA-seqã€histone<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Willem-Jan de Leeuw ; Anne Mensink ; Rianne G Bouma ; Fred van Leeuwen ; Joke M den HaanSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusDendritic cells (DCs) are important orchestrators of immune responses and can be divided into two conventional DC subsets, cDC1s and cDC2s, and a plasmacytoid DC (pDC) subset, which are involved in the activation of T cells and production of type I interferons (IFNs), respectively. The development of the DC subsets occurs in the bone marrow (BM) under control of different transcription factors and epigenetic modifiers. The histone methyltransferase DOT1L, known as a druggable target in cancer, is emerging as a key epigenetic regulator of differentiation in lymphocytes. DOT1L writes methylation of lysine 79 of histone H3 in gene bodies of actively transcribed genes. Deletion or inhibition of DOT1L affects the differentiation trajectory of innate and adaptive immune cells, leading to altered cell states. Recent studies suggest that DOT1L also plays a role in DC function. Here, we investigated the role of DOT1L in the development of DCs in in vitro BM cultures and in vivo using a tamoxifen-inducible mouse model. H3K79me2 ChIPseq data of sorted DC subsets from the BM revealed distinct H3K79me2 peaks for all three subsets, which suggested differential regulation of the subsets by DOT1L. A comparison of the H3K79me2 ChIPseq data to bulk RNAseq of sorted DC subsets from the BM revealed a stronger correlation between H3K79me2 and global transcription in pDCs and cDC2s compared to cDC1s. In line with this, we observed that Dot1l deletion led to a decrease in pDCs and CpG A-stimulated IFNÎ± production and an increase in cDC2s in in vitro BM cultures, while cDC1s were unchanged. In vivo deletion of Dot1l led to a decrease in common myeloid progenitors (CMPs), monocyte DC progenitors (MDPs), and common DC progenitors (CDPs) in the BM, while common lymphoid progenitor (CLP) and cDC2 numbers were increased. Inhibition of DOT1L resulted in a similar phenotype, which linked the observed effects to the methyltransferase activity of DOT1L. Interestingly, all Dot1l-KO DC subsets exhibited an enrichment of pathways related to antigen presentation and the immune response and MHCII expression was upregulated in Dot1l-KO pDCs and cDC2s in vivo. To conclude, our data indicate that DOT1L function differentially affects the development of DCs with predominant effects in pDCs and cDC2s.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301937" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE292814 FGFRæŠ‘åˆ¶å‰‚å…‹æœè‡´ç™Œæ€§PIK3CAé©±åŠ¨çš„æµ†æ¶²æ€§å­å®«å†…è†œç™Œçš„æ²»ç–—è€è¯æ€§å’Œå…ç–«é€ƒé€¸</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€regex:onco(logy|logist|gene|genic)ã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Xin ChengSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusWe developed the first clinically relevant, immunocompetent SEC mouse model incorporating PIK3CA mutation, TP53 loss, and MYC overexpression. Through comprehensive analysis integrating mouse models, human cell lines, xenografts, and clinical samples, we investigated mechanisms of PIK3CA-targeted therapy resistance. Single-cell transcriptional profiling identified FGFR1/2 association with intrinsic resistance and FGFR3 with acquired resistance. Dual inhibition of FGFR and PI3Ka achieved enhanced tumor suppression. Additionally, we discovered that FGFR signaling promotes immune evasion by downregulating MHC-I/HLA-mediated antigen processing and presentation. Importantly, FGFR inhibition not only reversed immune suppression by restoring antigen presentation but also demonstrated a synergistic effect with anti-PD-1 therapy, enhancing immunotherapy response and anti-tumor immune memory. Our findings reveal FGFR's dual role in therapy resistance and immune evasion, supporting FGFR inhibition as a promising strategy to enhance treatment outcome in SEC patients.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292814" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE320216 ä¹³è…ºç™Œè¿›å±•è¿‡ç¨‹ä¸­åŸºå› ç»„é‡ç»„åŠå…¶åŠŸèƒ½å½±å“ [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€RNA-seqã€genome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Kathleen S Reed ; Tom Misteli ; Andrew Fritz ; Haley Greenyer ; Seth Frietze ; Janet Stein ; Gary SteinSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTo explore how chromatin structure and epigenetic parameters of genome architecture changes during cancer progression at a fine scale and genome-wide, we generated high-resolution Micro-C contact maps in non-malignant, pre-cancerous, and metastatic MCF10 breast cancer epithelial cells. We profiled progression-associated reorganization of chromatin compartments, topologically associated domains (TADs), and chromatin loops, and also identified invariable chromatin features. We find large-scale compartmental shifts occur predominantly in early stages of cancer development, with more fine-scale structural changes in TADs and looping accumulating during the later transition to metastasis. We related these structural features to changes in gene expression, histone marks, and potential enhancers and found a large portion of differentially expressed genes physically connected to distal regulatory elements. While changes in chromatin loops were relatively rare during progression, differential loops were enriched for progression-associated genes, including those involved in proliferation, angiogenesis, and differentiation. Changes in either enhancer-promoter contacts or distal enhancer activity were accompanied by differential gene regulation, suggesting that changes in chromatin contacts are not necessary but can be sufficient for gene regulation. Together, our results demonstrate a functionally relevant connection between gene regulation and genome remodeling at many key genes during cancer progression.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320216" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE320215 ä¹³è…ºç™Œè¿›å±•è¿‡ç¨‹ä¸­åŸºå› ç»„é‡ç»„åŠå…¶åŠŸèƒ½å½±å“ [ATAC-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€ATAC-seqã€genome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Kathleen S Reed ; Tom Misteli ; Andrew Fritz ; Haley Greenyer ; Seth Frietze ; Janet Stein ; Gary SteinSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensTo explore how chromatin structure and epigenetic parameters of genome architecture changes during cancer progression at a fine scale and genome-wide, we generated high-resolution Micro-C contact maps in non-malignant, pre-cancerous, and metastatic MCF10 breast cancer epithelial cells. We profiled progression-associated reorganization of chromatin compartments, topologically associated domains (TADs), and chromatin loops, and also identified invariable chromatin features. We find large-scale compartmental shifts occur predominantly in early stages of cancer development, with more fine-scale structural changes in TADs and looping accumulating during the later transition to metastasis. We related these structural features to changes in gene expression, histone marks, and potential enhancers and found a large portion of differentially expressed genes physically connected to distal regulatory elements. While changes in chromatin loops were relatively rare during progression, differential loops were enriched for progression-associated genes, including those involved in proliferation, angiogenesis, and differentiation. Changes in either enhancer-promoter contacts or distal enhancer activity were accompanied by differential gene regulation, suggesting that changes in chromatin contacts are not necessary but can be sufficient for gene regulation. Together, our results demonstrate a functionally relevant connection between gene regulation and genome remodeling at many key genes during cancer progression.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320215" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE315728 MS æ‚£è€…è‚ é“ä¸­å›è‚ ä¸Šçš®å’Œå…ç–«ç»†èƒè°±çš„æ”¹å˜ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€regex:intestin(e|al)<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Shohei Suzuki ; Kentaro Miyamoto ; Jonathan Moody ; Tomohisa SujinoSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe intestinal epithelium plays a critical role in immuneâ€“microbiota interactions, yet its contribution to systemic autoimmunity remains unclear. Here, we identify intestinal epithelial cells (IECs) as key initiators of experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis (MS). In MS patients, IECs upregulate antigen presentationâ€“related genes and associate with increased intestinal Th17 cell accumulation.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315728" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE320388 æ°®ä»£è°¢è°±åˆ†ææ­ç¤ºç»†èƒçŠ¶æ€ç‰¹å¼‚æ€§å˜§å•¶åˆæˆé€”å¾„é€‰æ‹©</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmetabolismã€pathway<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Milan R Savani ; Bingbing Li ; Tracey Shipman ; Samuel K McBrayerSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensStable isotope tracing assays track few metabolites, yet cells use many nutrients to sustain nitrogen metabolism. Here, we create a platform for tracing 30 nitrogen isotope-labeled metabolites in parallel to enable a system-level understanding of cellular nitrogen metabolism. This platform reveals that while primitive cells engage both de novo and salvage pyrimidine synthesis pathways, differentiated cells nearly exclusively salvage uridine. This link between cell state and pyrimidine synthesis pathway preference persists in murine and human tissues. Mechanistically, we find that S1900 phosphorylation of CAD, the first enzyme of the de novo pathway, is induced by uridine deprivation in differentiated cells and constitutively enriched in primitive cells. Mimicking CAD S1900 phosphorylation in differentiated cells constitutively activates de novo pyrimidine synthesis, while blocking this modification impairs the cellular response to uridine starvation. Collectively, we establish a method for nitrogen metabolism profiling and define a mechanism of cell state-specific pyrimidine synthesis pathway choice.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320388" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE308878 çº¤æ¯›ç»†èƒé€šè¿‡STINGä»‹å¯¼çš„è‚¿ç˜¤æŠ‘åˆ¶çš„å…ç–«éä¾èµ–æ€§æœºåˆ¶é˜»æ­¢è‚¿ç˜¤å‘ç”Ÿ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immune<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jose A Colina ; Rong Wu ; Brian Magnuson ; Kathleen R Cho ; Analisa DiFeoSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusMitigating DNA damage in the fallopian tube epithelium (FTE) is essential for preventing tubo-ovarian high-grade serous carcinoma (HGSC). Here we demonstrate that Stimulator of Interferon Genes (STING) is abundantly expressed in the ciliated cells of the FTE and functions as a critical immune-independent tumor suppressor. Using patient samples, mouse models, and organoid systems, we demonstrate that ciliated cells mount a dual protective response to ovulation-associated genotoxic stress: intrinsic STING-driven apoptosis and extrinsic clearance of neighboring damaged secretory cells via TNFÎ± secretion. This surveillance mechanism markedly limits DNA damage accumulation within the epithelial microenvironment. Crucially, while these mechanisms are vital for maintaining homeostasis and reducing genomic instability, they fail to impact p53-deficient precursor lesions as both intrinsic and extrinsic pro-apoptotic processes rely on functional p53 signaling. These findings redefine ciliated cells as key guardians of genome integrity rather than passive bystanders and implicate early loss of STING-high ciliated cells as a pivotal event in HGSC initiation with potential relevance for prevention and therapeutic intervention.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308878" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 42 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (1æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>é˜¿å°”èŒ¨æµ·é»˜ç—…å¯èƒ½å§‹äºè„‘è¡€æµé‡çš„æ‚„ç„¶ä¸‹é™ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSubtle changes in brain blood flow and oxygen use are closely linked to hallmark signs of Alzheimerâ€™s, including amyloid plaques and memory-related brain shrinkage. Simple, noninvasive scans may one day help spot risk earlierâ€”by looking at the brainâ€™s vascular health, not just its plaques.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/02/260224023159.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA-seq</td>
<td>10</td>
</tr>
<tr>
<td>immune</td>
<td>6</td>
</tr>
<tr>
<td>histone</td>
<td>6</td>
</tr>
<tr>
<td>cancer</td>
<td>6</td>
</tr>
<tr>
<td>genome</td>
<td>5</td>
</tr>
<tr>
<td>macrophage</td>
<td>5</td>
</tr>
<tr>
<td>tumor</td>
<td>4</td>
</tr>
<tr>
<td>metabolic</td>
<td>3</td>
</tr>
<tr>
<td>inflammation</td>
<td>3</td>
</tr>
<tr>
<td>scRNA</td>
<td>3</td>
</tr>
<tr>
<td>regex:intestin(e</td>
<td>al)</td>
</tr>
<tr>
<td>regex:onco(logy</td>
<td>logist</td>
</tr>
<tr>
<td>resistance</td>
<td>2</td>
</tr>
<tr>
<td>metabolism</td>
<td>2</td>
</tr>
<tr>
<td>dendritic cell</td>
<td>2</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>2</td>
</tr>
<tr>
<td>ATAC-seq</td>
<td>2</td>
</tr>
<tr>
<td>transcriptome</td>
<td>2</td>
</tr>
<tr>
<td>carcinoma</td>
<td>2</td>
</tr>
<tr>
<td>bioinformatics</td>
<td>1</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (42æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300991" target="_blank" rel="noopener noreferrer">å¯¹ä»å°é¼ ä¹³è…ºè‚¿ç˜¤ä¸­åˆ†ç¦»çš„ CD45 é˜³æ€§ç»†èƒè¿›è¡Œäº† GSE300991 å•ç»†èƒ RNA æµ‹åºåˆ†æã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281293" target="_blank" rel="noopener noreferrer">GSE281293 KSHVè£‚è§£æ€§å†æ¿€æ´»åçš„å…¨åŸºå› ç»„è½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319658" target="_blank" rel="noopener noreferrer">GSE319658 é€‰æ‹©æ€§é¶å‘ç»„è›‹ç™½æ ·æ²‰é»˜å­ Sfx è‡³ R6K æ¥åˆè½¬ç§»æ“çºµå­ [ChIP-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319657" target="_blank" rel="noopener noreferrer">GSE319657 ç»„è›‹ç™½æ ·æ²‰é»˜å­ Sfx é€‰æ‹©æ€§é¶å‘ R6K æ¥åˆè½¬ç§»æ“çºµå­ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320319" target="_blank" rel="noopener noreferrer">GSE320319 åŸºå› ç»„é‡ç»„åŠå…¶åœ¨ä¹³è…ºç™Œè¿›å±•è¿‡ç¨‹ä¸­çš„åŠŸèƒ½å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302079" target="_blank" rel="noopener noreferrer">GSE302079 è†€èƒ±ç™ŒåŸºå› å·¥ç¨‹å°é¼ æ¨¡å‹è¡ç”Ÿè‚¿ç˜¤ç»†èƒç³»çš„è¡¨å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287674" target="_blank" rel="noopener noreferrer">GSE287674 MafB æ˜¯è·¨ç»„ç»‡å’Œç‰©ç§çš„å·¨å™¬ç»†èƒå‘è‚²å’Œèº«ä»½çš„ä¿å®ˆè½¬å½•è°ƒèŠ‚å› å­ [scRNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286897" target="_blank" rel="noopener noreferrer">GSE286897 MafB æ˜¯è·¨ç»„ç»‡å’Œç‰©ç§çš„å·¨å™¬ç»†èƒå‘è‚²å’Œèº«ä»½çš„ä¿å®ˆè½¬å½•è°ƒèŠ‚å› å­ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320312" target="_blank" rel="noopener noreferrer">GSE320312 æŠ—TIM3-IFNèåˆè›‹ç™½é€šè¿‡æ¿€æ´»è‚¿ç˜¤å†…æ ‘çªçŠ¶ç»†èƒï¼Œä½¿è‚¿ç˜¤æµ¸æ¶¦çš„è€—ç«­TIM3+CD8+Tç»†èƒæ¢å¤æ´»åŠ›</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320308" target="_blank" rel="noopener noreferrer">GSE320308 PD0325901 Alleviates Thrombin-Inhibited Osteogenic Differentiation Through an IL-1Î²-Activated Feedback Loop between MEK-Erk1/2 and NF-ÎºB Signal Pathways: Insights from Bioinformatics and Experimental Verification</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307339" target="_blank" rel="noopener noreferrer">GSE307339 ç‚ç—‡å¢å¼ºæˆå¹´APPå°èƒ¶è´¨ç»†èƒåœ¨å¾®æµæ§ç¥ç»å…ƒ-å°èƒ¶è´¨ç»†èƒå…±åŸ¹å…»æ¨¡å‹ä¸­çš„çªè§¦ç‰¹å¼‚æ€§åå™¬ä½œç”¨</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305554" target="_blank" rel="noopener noreferrer">GSE305554 m6A è¡¨è§‚è½¬å½•ç»„è°ƒæ§è§†ç½‘è†œç¥ç»èŠ‚ç»†èƒçš„è½´çªå‘ç”Ÿå’Œé‡ç¼–ç¨‹ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296812" target="_blank" rel="noopener noreferrer">GSE296812ï¼šç»„è›‹ç™½ä¿®é¥°æ—¶é’Ÿåœ¨è·¨ç‰©ç§ç”Ÿç‰©å¹´é¾„é¢„æµ‹ä¸­çš„ç¨³å¥åº”ç”¨åŠè¡°è€è°ƒæ§æœºåˆ¶çš„é˜æ˜</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE234721" target="_blank" rel="noopener noreferrer">GSE234721 æœè‡ piRNA ç°‡å¼‚æŸ“è‰²è´¨åœ¨æ€¥æ€§çƒ­ä¼‘å…‹åçš„å¿«é€Ÿè§£ä½“å’Œ Piwi éä¾èµ–æ€§é‡ç»„ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315447" target="_blank" rel="noopener noreferrer">GSE315447 22q11.2å¾®ç¼ºå¤±ä½ç‚¹ç¼–ç çš„å•å€ä½“ä¸è¶³çº¿ç²’ä½“åŸºå› ä¹‹é—´çš„æŠ‘åˆ¶æ€§é—ä¼ ç›¸äº’ä½œç”¨å†³å®šäº†å¤§è„‘å’Œå¿ƒè„è¡¨å‹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307353" target="_blank" rel="noopener noreferrer">GSE307353 Siglec-F å¯ä¿æŠ¤å°é¼ å…å—å¼¹æ€§è›‹ç™½é…¶è¯±å¯¼çš„è‚ºéƒ¨ç‚ç—‡å’Œè‚ºæ°”è‚¿</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304577" target="_blank" rel="noopener noreferrer">GSE304577 æ…¢æ€§å¯å¡å› ä½¿ç”¨éšœç¢ä¸­å£è…”åˆ°è¡€æ¶²å¾®ç”Ÿç‰©DNAæ˜“ä½çš„ç‰¹å¾åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292232" target="_blank" rel="noopener noreferrer">GSE292232 å°é¼ åè‚¢éª¨éª¼è‚Œåœ¨èƒšèƒæœŸå’Œæˆå¹´æœŸæ…¢è‚Œçº¤ç»´å«é‡å·®å¼‚çš„åŸºå› ç»„ç‰¹å¾[RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292230" target="_blank" rel="noopener noreferrer">GSE292230 å°é¼ åè‚¢éª¨éª¼è‚Œåœ¨èƒšèƒæœŸå’Œæˆå¹´æœŸæ…¢è‚Œçº¤ç»´å«é‡å·®å¼‚çš„åŸºå› ç»„ç‰¹å¾ [ATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE281295" target="_blank" rel="noopener noreferrer">GSE281295 KSHVè£‚è§£æ€§å†æ¿€æ´»è¿‡ç¨‹ä¸­ç»†èƒmiRNAè½¬å½•ç»„çš„ç‰¹å¾åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315102" target="_blank" rel="noopener noreferrer">GSE315102 ç™½ç»†èƒä»‹ç´ -2-TGF-Î² æ›¿ä»£æ¿€åŠ¨å‰‚å¯è½»æ¾è¯±å¯¼å…ç–«è€å—</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314399" target="_blank" rel="noopener noreferrer">GSE314399 äººç±» Flower åŒå·¥å‹ hFWE4 ä¿ƒè¿›çš®è‚¤é³çŠ¶ç»†èƒç™Œçš„è§’åŒ–</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313932" target="_blank" rel="noopener noreferrer">GSE313932 FOXO1 æ•´åˆåŠ¨è„‰ç²¥æ ·ç¡¬åŒ–ä¸­çš„å†…çš®è¡€æµåŠ¨åŠ›å­¦ã€ç‚ç—‡å’Œä»£è°¢é€šè·¯ [LSS]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313931" target="_blank" rel="noopener noreferrer">GSE313931 FOXO1 æ•´åˆåŠ¨è„‰ç²¥æ ·ç¡¬åŒ–ä¸­çš„å†…çš®è¡€æµåŠ¨åŠ›å­¦ã€ç‚ç—‡å’Œä»£è°¢é€šè·¯ [OSS]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285051" target="_blank" rel="noopener noreferrer">GSE285051 äººç±»å¹²ç»†èƒè¡ç”Ÿç¾ä¸¸æ ·ç±»å™¨å®˜ä¸­å¤šç§ç¾ä¸¸ç»†èƒè°±ç³»çš„å‡ºç° [scRNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285050" target="_blank" rel="noopener noreferrer">GSE285050 äººç±»å¹²ç»†èƒè¡ç”Ÿç¾ä¸¸æ ·ç±»å™¨å®˜ä¸­å¤šç§ç¾ä¸¸ç»†èƒè°±ç³»çš„å‡ºç° [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268687" target="_blank" rel="noopener noreferrer">GSE268687 nBAFå¤åˆç‰©äºšåŸºCREST/SS18L1é€šè¿‡é…ªæ°¨é…¸397å’Œç»„è›‹ç™½ä¹™é…°è½¬ç§»é…¶CBPè°ƒèŠ‚æµ·é©¬è®°å¿†è¿‡ç¨‹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE243065" target="_blank" rel="noopener noreferrer">GSE243065 åŸºå› ç»„ç¼–è¾‘ä¸­æœ€å¤§é™åº¦å‡å°‘å¤§èŒƒå›´æŸ“è‰²è´¨æ‰°åŠ¨å¯ä¿æŠ¤å¹²ç»†èƒç‰¹æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320155" target="_blank" rel="noopener noreferrer">GSE320155 äººç±»è‚å†… CD4âº T ç»†èƒçš„å•ç»†èƒ RNA æµ‹åºç»“æœæ­ç¤ºäº†å¥åº·è‚è„å’Œè‚ç»†èƒç™Œ (HCC) è‚è„æ ·æœ¬ä¸­ç‹¬ç‰¹çš„ Treg è½¬å½•ç‰¹å¾å’Œä¸¤ç§ç¨³æ€ç»„ç»‡é€‚åº”ç¨‹åºã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE320120" target="_blank" rel="noopener noreferrer">GSE320120 ç¡«ä»£é»„ç´ é€šè¿‡é‡å¡‘é…µæ¯è½¬å½•å’Œä»£è°¢å»¶é•¿å¤åˆ¶å¯¿å‘½</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303683" target="_blank" rel="noopener noreferrer">GSE303683 RNA-seq æ•°æ®æ¥è‡ª GBM æ‚£è€…å’Œé…å¯¹ç±»å™¨å®˜</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303409" target="_blank" rel="noopener noreferrer">GSE303409 é‰´å®šè‚ºç™Œæ”¾å°„æŠ—æ€§åŸºå›  [CRISPR ç­›é€‰]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303209" target="_blank" rel="noopener noreferrer">GSE303209 è‚ éšçªæ˜¯æˆŠå‹è‚ç‚ç—…æ¯’æ„ŸæŸ“çš„æ½œåœ¨å‚¨å­˜åº“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299009" target="_blank" rel="noopener noreferrer">GSE299009 ä½å¼ºåº¦è¶…å£° (LIUS) è¯±å¯¼çš„éå°ç»†èƒè‚ºç™Œ (NSCLC) ç»†èƒç³»è½¬å½•ç»„æ”¹å˜ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295920" target="_blank" rel="noopener noreferrer">GSE295920 è†€èƒ±ç™Œçš„åŸºå› å·¥ç¨‹å°é¼ æ¨¡å‹å’ŒåŒåŸºå› ç§»æ¤æ¨¡å‹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291409" target="_blank" rel="noopener noreferrer">GSE291409 BALF åŸºå› è¡¨è¾¾è°±åˆ†ææ­ç¤ºäº† COVID-19 åæŒç»­æ€§ ILD ä¸­å…ˆå¤©å…ç–«æ¿€æ´»çš„åå€š</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290421" target="_blank" rel="noopener noreferrer">GSE290421 äºŒåäºŒç¢³å…­çƒ¯é…¸é€šè¿‡å…¶æ°§è„‚è´¨ä¿æŠ¤è‚ºéƒ¨å…å—è‡­æ°§è¯±å¯¼çš„ç‚ç—‡ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290387" target="_blank" rel="noopener noreferrer">GSE290387 å¯¹ 1-5 å²å¹¼å„¿é¼»è…”åˆ®åŒ™æˆ–æ‹­å­æ ·æœ¬è¿›è¡Œ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287476" target="_blank" rel="noopener noreferrer">GSE287476 MafB æ˜¯è·¨ç»„ç»‡å’Œç‰©ç§çš„å·¨å™¬ç»†èƒå‘è‚²å’Œèº«ä»½çš„ä¿å®ˆè½¬å½•è°ƒèŠ‚å› å­ [CUT&amp;RUN 2]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287347" target="_blank" rel="noopener noreferrer">GSE287347 MafB æ˜¯å·¨å™¬ç»†èƒå‘è‚²å’Œç‰¹æ€§åœ¨ä¸åŒç»„ç»‡å’Œç‰©ç§ä¸­ä¿å®ˆçš„è½¬å½•è°ƒæ§å› å­ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287346" target="_blank" rel="noopener noreferrer">GSE287346 MafB æ˜¯è·¨ç»„ç»‡å’Œç‰©ç§çš„å·¨å™¬ç»†èƒå‘è‚²å’Œèº«ä»½çš„ä¿å®ˆè½¬å½•è°ƒèŠ‚å› å­ [CUT&amp;Run]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE272963" target="_blank" rel="noopener noreferrer">GSE272963 æ¶æ€§ç–ŸåŸâ€‹â€‹è™«ä¸´åºŠæ ·æœ¬ä¸­çº¿ç²’ä½“å¤©ç„¶åä¹‰è½¬å½•æœ¬çš„å·®å¼‚è¡¨è¾¾åœ¨å¤šç§ç–¾ç—…è¡¨å‹ä¸­çš„ç ”ç©¶</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-02-25 21:53</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>